Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q08289

UPID:
CACB2_HUMAN

ALTERNATIVE NAMES:
Calcium channel voltage-dependent subunit beta 2; Lambert-Eaton myasthenic syndrome antigen B

ALTERNATIVE UPACC:
Q08289; A6PVM5; A6PVM7; A6PVM8; O00304; Q5QJ99; Q5QJA0; Q5VVG9; Q5VVH0; Q5VWV6; Q6TME1; Q6TME2; Q6TME3; Q8WX81; Q96NZ3; Q96NZ4; Q96NZ5; Q9BWU2; Q9HD32; Q9Y340; Q9Y341

BACKGROUND:
Voltage-dependent L-type calcium channel subunit beta-2, identified by its involvement in calcium current modulation and membrane targeting of the alpha-1 subunit CACNA1C, is essential for heart rate and muscle contraction regulation. Its alternative names include Calcium channel voltage-dependent subunit beta 2 and Lambert-Eaton myasthenic syndrome antigen B.

THERAPEUTIC SIGNIFICANCE:
The protein's association with Brugada syndrome 4, characterized by dangerous heart rhythms, underscores its therapeutic significance. Exploring the Voltage-dependent L-type calcium channel subunit beta-2's role could lead to innovative treatments for cardiac arrhythmias, offering hope for patients with this and potentially other related cardiovascular conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.